Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grosz, Daniel E
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Active, not recruiting	3	1667	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	06/24	03/26
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24